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In 2009, influenza A(H1N1)pdm09 virus caused a global pandemic and is now around as a 
seasonal epidemic peaking from December to March. It was confirmed that influenza 
A(H1N1)pdm09 is resistant to amantadine treatment. To treat people with severe illness, 
the World Health Organisation (WHO) recommended using oseltamivir or alternatively 
zanamivir if there were signs of resistance to the former. Because of the risk for emerging 
resistance, a next generation of antivirals against the virus is needed. 
 
Recently, studies of influenza virus-host interactions revealed a number of host proteins 
that are potential targets for antivirals. Special interest goes to Raf/MEK/ERK, NF-κB, 
PI3K/Akt and PKC signaling pathways (Planz, 2013). It is proposed that inhibition of host 
factors is less likely to cause resistance and more importantly, a lot of these inhibitors are 
in development or already approved for other diseases such as cancer . Repurposing of 
these drugs is facilitated, because much is known about their toxicity and working 
mechanism. 
 
The present study suggests an important role for Akt in influenza A(H1N1)pdm09 virus 
infections and that MK-2206 could be further developed as an antiviral against influenza 
A(H1N1)pdm09 viruses. MK-2206 accumulates in endocytic compartments and blocks the 
release of the virus in the cytoplasm. 
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List of symbols 
 
5’ppp 5’-triphosphate 
APAF-1 apoptotic protease-activating factor 1 
APC  antigen-presenting cells  
ASC apoptosis associated speck-like protein containing a CARD 
ATP adenosine triphosphate 
ATS quantitative activity and toxicity score 
BAK  Bcl-2 homologous antagonist/killer 
BAX  Bcl-2-associated X protein 
BCR  B cell receptors (BCR) 
BH3 Bcl-2 homology 3 
BID  BH3 interacting-domain death agonist 
BSA bovine serum albumin 
CAK CDK-activating-kinase 
CARD  Caspase activation and recruitment domain 
CDK Cyclin-dependent kinase 
CPSF cleavage and polyadenylation specificity protein 
Crm1 Chromosome region maintenance 1 protein 
CTD carboxy-terminal domain 
CTG Cell Titer Glo 
DISC death-inducing  signaling complex 
DMEM Dulbecco's Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
DSIF 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole sensitivity-inducing factor 
eIF2α Eukaryotic initiation factor 2 alpha 
eIF3(e) Eukaryotic initiation factor 3(e) 
FADD  Fas-Associated protein with Death Domain 
FBS fetal bovine serum 
HA haemagglutinin 
HIV-1 human immunodeficiency virus type 1 
hpi hours post infection 
HSV  herpes simplex virus 
GAS IFN-γ-activated site 
  
GSK-3β glycogen synthase kinase-3β 
GTP guanosine triphosphate 
IAV influenza A virus 
IFN interferon 
IFNAR1 interferon (alpha, beta and omega) receptor 1 
IFNAR2 interferon (alpha, beta and omega) receptor 2 
IL interleukin 
IPS-1 β-interferon promoter stimulator 1 
IRAK interleukin-1 receptor-associated kinase 
IRF interferon regulatory transcription factor 
ISG IFN stimulated genes 
ISRE sensitive response elements 
JAK  Janus activated kinase 
LGP2 Laboratory of genetics and physiology 2 
LRR Leucine rich repeats 
M matrix proteins 
m7G 7-methylguanosine 
M1 matrix protein 1 
M2 matrix protein 2 
MAPK mitogen-activated protein kinases 
MDA5 melonoma differentiation associated antigen 5 
MDCK Madin-Darby canine kidney 
MHC major histocompatibility complex 
moi multiplicity of infection 
MOMP  mitochondrial outer membrane permeabilization 
MyD88 myeloid differentiation primary response gene 88 
NA neuraminidase 
NELF negative elongation factor 
NEP nuclear export protein 
NK cells  natural killer cells 
NLR nucleotide-binding domain, leucine-rich repeat-containing proteins 
NP nucleocapsid protein 
NPC nuclear pore complexes 
NS non-structural proteins 
  
NS1 non-structural protein 1 
PA polymerase acidic protein 
PABII poly(A)-binding protein II 
PACT protein activator of the interferon-induced protein kinase 
PAMPs  pathogen associated molecular patterns 
PB1 polymerase basic protein 1 
PB2 polymerase basic protein 2 
PBS phosphate buffered saline 
PCI Pharmacological CDK inhibitors 
pDC plasmacytoid dendritic cell 
PFU plaque forming units 
PKR protein kinase RNA regulated 
PRR pattern recognition receptor 
RanBP5  β-importin Ran binding protein 5 
Ran Ras-related nuclear protein 
RdRP  RNA dependent RNA polymerase 
RIG-I retinoic acid-inducible gene-I 
RIP-1 receptor-interacting protein 1 
NLR NOD-like receptor 
RNP ribonucleoprotein 
RT-qPCR reverse transcriptase quantitative polymerase chain reaction 
SaliPhe saliphenylhalamide 
STAT  signal transducer and activator of transcription 
TBK1 TRAF family member-associated NF-κB activator binding kinase 1 
TIR Toll/IL-1 receptor 
TLR toll-like receptor 
TNF  tumor necrosis factor 
TPCK L-1-tosylamido-2-phenylethyl chloromethyl ketone 
TRAF TNF receptor associated factor 
TRIF TIR domain-containing adaptor protein inducing IFN-β 
TRIM25 tripartite motif-containing protein 25 
vATPase cellular vacuolar ATPase 
VGM virus growth medium 
WHO World Health Organisation 
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1 Introduction 
 
In 2009, Influenza A(H1N1)pdm09 virus caused a global pandemic and is now around 
as a seasonal epidemic peaking from December to March. It was confirmed that 
influenza A(H1N1)pdm09 is resistant to amantadine treatment. To treat people with 
severe illness, the World Health Organisation (WHO) recommended using oseltamivir 
or alternatively zanamivir if there were signs of resistance to the former. Because of 
the risk for emerging resistance, a next generation of antivirals against the virus is 
needed (Schang et al., 2001). 
 
Recently, studies of influenza virus-host interactions revealed a number of host 
proteins that are potential targets for antivirals. Special interest goes to Raf/MEK/ERK, 
NF-κB, PI3K/Akt and PKC signaling pathways (Planz, 2013). It is proposed that 
inhibition of host factors is less likely to cause resistance and more importantly, a lot of 
these inhibitors are in development or already approved for other diseases such as 
cancer (www.clinicaltrials.gov). Repurposing of these drugs is facilitated, because 
much is known about their toxicity and working mechanism. 
 
In this study, the role of four Akt-inhibitors were tested for their antiviral activities 
against influenza A(H1N1)pdm09. 
 
First, this study briefly discusses flu and the emergence of pandemics. Next, the 
properties of the influenza A virus are introduced. Then the role of the immune system 
in the recognition of the virus is explained. After showing how the virus tries to evade 
the immune system, antiviral drugs are discussed. Finally the results of the testing with 
Akt-inhibitors are discussed. 
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2 Theoretical Background 
 
In this part of the study flu, the virus that causes it and how the immune system tries 
to clear the infection are discussed. Next the fact that influenza A viruses are able to 
regulate some of the immune reactions to ensure successful replication are discussed. 
Finally,  the mechanisms of antivirals against influenza A are explained.  
 
2.1 Flu 
 
Infuenza A viruses (IAV) cause influenza, commonly known as flu. It is a highly 
contagious disease of the respiratory tract which causes a feverish illness that can lead 
to death. Influenza A viruses are responsible for periodic global pandemics with high 
mortality rates. In 1918 a pandemic caused about 50 million deaths all over the world, 
which makes it the most devastating pandemic known until today (Taubenberger & 
Kash, 2010).  
 
Normally flu is a self-limiting disease that infects all age groups. Young children, elderly 
people and people with immunodeficiency are more susceptible to pneumonia and 
lethal infections. 
 
The disease can be transmitted from human to human through mucus produced in the 
airways. Sneezing and coughing creates aerosols which can be inhaled by persons in 
the surrounding area. Also direct contact with mucus can infect others. It is therefore 
very important to apply a good hand and respiratory hygiene. When feeling sick, it is 
advised to stay at home to prevent transmission to other persons. IAV spreads very 
fast in younger population, because they are lacking antibodies to the virus (WHO). 
 
Flu is characterized by fever, headaches, coughing, sore throat, muscle pain, stuffy 
nose, loss of appetite and fatigue. It is hard to identify if someone has flu or a common 
cold which is caused by rhinoviruses and coronaviruses. A study by Monto et al. (2000) 
mainly performed on adults, created a model to distinguish between the diseases. It 
was found that the main predictors were fever and coughing (Table 1).  
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Table 1. Modeling the influenza symptoms (Monto et al., 2000) 
 
Multivariate analysis showed that the combination of both fever and cough (onset after 
36h) is the best combination to predict whether the patient is infected with influenza or 
has a common cold. According to the positive predicted value, people who have both 
symptoms have 77 – 85 percent chance of having laboratory-confirmed influenza 
(Monto et al., 2000). 
 
2.2 Pandemics 
 
In the last 500 years, there have been at least 14 IAV pandemics. An overview of the 
evolution of the pandemic viruses can be found in Figure 1. The worst pandemic 
known occurred in 1918 and was responsible for approximately 675,000 deaths in the 
U.S. and about 50 million people worldwide (Johnson & Mueller, 2002). The “Spanish 
flu”, as it was called, had an extremely high mortality owing to the result of bacterial 
infection of the lungs (pneumonia) and an unexplained peak in child deaths. It is a 
H1N1 type of IAV and continued to circulate for nearly 40 years. Later, in 1977 it 
reappeared and is still around at this moment (Taubenberger & Kash, 2010). 
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Figure 1. Emerge of new IAV strains (Taubenberger & Kash, 2010) 
 
In 1957 the “Asian flu” pandemic occurred through reassortment. The haemagglutinin 
(HA) and neuraminidase (NA) genes of the 1918 H1N1 virus got substituted by avian-
like H2 and N2 subtypes and also PB1 was changed. The H2N2 IAV remained active for 
about 11 years and killed about 4 million people (Oxford, 2000). It has not returned up 
to the present (Taubenberger & Kash, 2010). 
 
The 1968 “Hong Kong” pandemic is subtyped H3N2 and was formed by reassortment 
between the human H2N2 virus and an avian variant. It was responsible for 2 million 
deaths (Oxford, 2000). HA and polymerase basic protein 1 (PB1) segments were 
changed. The virus still had the N2 type NA of the previously circulating Asian flu and 
because a lot of people already had antibodies for this NA subtype, the virus was quite 
mild. It didn’t take much time before the virus turned endemic and began circulating as 
a seasonal flu (Taubenberger & Kash, 2010). 
 
In 1977, a descendant of the 1918 H1N1 virus that disappeared in 1957 started to 
recirculate. It is very unlikely that the virus was able to ‘survive’ in a population with 
high natural immunity and vaccines. Because genetic analyses proved that all eight 
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segments were nearly identical to the 1918 variant, it has been suggested that a 
frozen strain from early 1950s was released. The virus is still around today 
(Taubenberger & Kash, 2010). 
 
More recently, in 2009, a new H1N1 type virus arose. As seen in Figure 1, first a triple 
reassortment H1N2 swine flu was formed by combination of avian-like influenza, North 
American swine flu and the H3N2 strain. It became pandemic when segments were 
exchanged with the Eurasian Swine H1N1. The result is a virus containing NA and 
matrix proteins (M) segments from the European avian like H1N1 lineage. HA, 
nucleocapsid protein (NP) and non-structural proteins (NS) originated from the 
classical swine H1N1. Avian IAV provided polymerase basic protein 1 (PB2) and 
polymerase acidic protein (PA) segments and the origin of the PB1 segment lies in the 
human seasonal H3N2 virus (Taubenberger & Kash, 2010). 
 
In the 2009 influenza season, 12.564 cases of Influenza A were reported in Finland. Of 
those cases, 7.646 were the pandemic swine flu, also called influenza A(H1N1)pdm09. 
Swine flu was first found in Finland in May and was responsible for 44 deaths in 2009 
(Hulkko et al., 2010). In 2010, swine flu became a seasonal epidemic and there were 
much less (418) cases of influenza A reported. Only 228 of swine flu cases were 
confirmed. This is probably because of the high coverage (51%) of pandemic 
vaccinations in 2009 or resistance due to an earlier infection (Hulkko et al., 2011). In 
2011, 1.900 influenza A cases were reported, of which 666 were pandemic (Jaakola et 
al., 2012). Swine flu was shown to be resistant to amantadine and research at FIMM 
found the first isolate in Finland that is resistant to both amantadine and oseltamivir. 
Worldwide, over 40 oseltamivir resistant isolates have been reported (WHO, 2009). 
 
2.3 Influenza A Virus 
 
Influenza A is a genus located in the family Orthomyxoviridae, which is characterized 
by an 8 segmented, negative-strand RNA genome. The viruses evolve continuously and 
can infect people multiple times in a lifetime. This evolution is due to mutations 
(antigenic drift) and reassortment (antigenic shift). Even though the different genera 
have a common ancestry, reassortment only occurs within the genera. Influenza A has 
different subtypes which are characterized by both haemagglutinin (HA) and 
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neuraminidase (NA), which are glycoproteins located in the lipid envelope of the virus. 
There are 16 variations of HA and 9 of NA. Beneath the surface, there are matrix 
proteins (matrix protein 1, M1) which support the lipid envelope. Ion channels (matrix 
protein 2, M2) are present in the virion as tetramers and are responsible for transport 
through the membrane. In the interior of the virion, there is RNA which is surrounded 
by nucleocapsid protein (NP) and joined with the RNA dependent RNA polymerase 
(PB1, PB2, PA). These structures are also called ribonucleoproteins (RNPs) (Bouvier & 
Palese, 2008). An overview of IAV’s structure can be found in Figure 2 (Racaniello, 
2009). 
 
 
Figure 2. Virion structure of influenza A virus (Racaniello, 2009) 
 
Also some nuclear export proteins (NEP) can be found inside the virion as it is used to 
export viral RNPs out of the cell nucleus (Samji, 2009). 
 
2.3.1 Genome 
 
As seen in Figure 3, the genome of IAV consists out of 8 single negative RNA segments 
and is about 13,500 bases long. Each segment encodes for one or two proteins by 
alternative splicing. PB1-F2 is somewhat different as it is established by a +1 shift of 
the open reading frame in the PB1 segment. The protein is typical for IAV and has no 
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analogs in influenza B and C. After infection it resides in the mitochondria and is able 
to overcome immune responses and increase apoptosis in immune cells (Dermody & 
Chappell, 2011). 
 
 
Figure 3. Genome of influenza A virus (Racaniello, 2009) 
 
The 8 stranded genome codes for 11 different proteins. Three proteins PB1, PB2 and 
PA form the RNA dependent RNA polymerase complex, which means that there are 
only 8 proteins left for other mechanisms. How the virus is able to replicate with this 
limited amount of proteins will be explained in next chapter. 
 
2.3.2 Replication 
 
Here the replication mechanism of influenza A viruses will be explained. Because of 
their limited amount of proteins, viruses are heavily dependent on host cells and use 
many host cellular pathways in their own advantage. Understanding these complex 
mechanisms is very important to understand and develop antiviral drugs. 
 
Binding of the virion  
IAV attach to sialic acid glycoproteins with haemaggluttinin protein. HA on influenza is 
a trimer and needs to be cleaved to be able to fuse the viral and cell endosomal 
membranes. Normally this is done by human proteases (such as Clara) in the 
respiratory tract, but when different cell lines are used in-vitro, trypsin has to be 
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added. HA is responsible for the selectivity of IAV as it decides which type of sialic 
acid-galactose linkage the virus can bind. Figure 4 illustrates two important 
configurations of the linkage. Human IAV prefer to bind sialic acid attached to 
galactose in an α(2,6)-configuration, while avian IAV prefer an α(2,3)-configuration (De 
Clerq, 2006; Bouvier & Palese, 2008). 
 
 
Figure 4. Types of sialic acid – galactose linkages (De Clerq, 2006) 
 
Although it is rare, humans can still get infected by an avian variant of IAV because 
human also possess a minor population of the α(2,3)-configuration in the lower 
respiratory tract (Shinya et al., 2006). 
 
Entering the cytoplasm 
The virus is taken into the cells by endocytosis. The process is illustrated in Figure 5. 
When getting closer to the cell nucleus, protons are pumped into the vesicle by cellular 
channels until pH 5 is reached. At this stage, the haemagglutinin undergoes a 
conformational change which allows the endosomal membrane and viral envelope to 
fuse (Stegmann, 2000).  
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Figure 5. Fusion of viral and endosomal membrane (Cross et al., 2004) 
 
At the same time, viral M2 protein tetramers transfer protons to the virion’s interior to 
weaken the interaction of the M1 protein layer with the viral RNPs (see Figure 6). M2 
has been a popular target for antiviral drugs such as amantadine. Amantadine binds to 
several amino acids which are located inside the M2 channel and blocks the entrance 
of protons. By preventing the acidification of the virion, M1-RNA cannot be split. 
 
 
Figure 6. M2 proton pump (Das et al, 2010) 
 
However, the M2 protein is subjected to many mutations, which prevents the operation 
of the antiviral drug. After release in the cytosol, the viral RNPs can enter the cell 
nucleus due to nuclear localization signals located on NP (Das et al, 2010). 
 
Entering the nucleus 
Transcription and replication are done in the cell nucleus. The cell nucleus is enclosed 
by a double membrane which contains nuclear pore complexes (NPC) for traffic 
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between the cytoplasm and nucleoplasm. Small molecules (<9 nm or 20-30 kDa) are 
able to pass through the NPCs by passive diffusion. Because vRNPs are bigger, they 
need the help of transport receptors that are able to pass through the NPC 
(Hutchinson et al., 2012). The process is illustrated in Figure 7. 
 
 Figure 7. Nuclear import of vRNPs (Cros & Palese, 2003) 
 
vRNPs enter the nucleus via the ‘classical import pathway’ . They bind karyopherin α1 
with the nuclear localization signal (NLS) which can be found on NP. Then karyopherin 
β binds the complex and allows the vRNP to be transported by Ras-related nuclear 
protein (Ran). Ran is a small protein driven by guanosine triphosphate (GTP) that 
shuttles between the cytoplasm and nucleus (Cros & Palese, 2003). 
 
Transcription and replication of viral RNA 
As soon as the vRNPs enter the nucleus, they start producing (+)mRNA that will be 
used for protein synthesis. The (-)vRNA doesn’t contain the sequence to produce a 7-
methylguanosine (m7G) cap that is required for functional mRNA and protect the mRNA 
from degradation by RNAse. Therefore the viral RNA dependent RNA polymerase 
(RdRP) needs to find an active host RNA polymerase II and steal the cap. This process 
is called ‘cap snatching’ and is illustrated in Figure 8 (Zhang et al., 2001).  
 
11 
 
First the vRNP binds a host cellular mRNA cap that is recognized by PB2. After binding 
with PB2, the RNA is cleaved approximately 10-13 bases from the cap-1 structure by 
PA. This cap forms the 5’-end of the new viral mRNA. After the addition of a guanosine 
nucleoside, a primer is formed and transcription starts. The template strand is read 
from 3’ to 5’ and transcription is done by PB1 (Zhang et al., 2001). When the 
polymerase hits the 5’ end of the template strain, they remain bound. Due to steric 
hinder, the polymerase begins to stutter-read and produces a poly(A)-tail (Pritlove et 
al., 1998; Poon et al., 1999; Zheng et al., 1999). 
 
 
Figure 8. Transcription of vRNA to viral mRNA (Zhang, 2001) 
 
To amplify the viral genome, (+)cRNA is formed. It is a complete copy of the vRNA 
and in contrary to mRNA, cRNA is not capped or polyadenylated. After transcription, 
cRNA becomes encapsidated by NP and the polymerase complex. The cRNA serves as 
a template for vRNP amplification (Zhang et al, 2010). 
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Multiplication of vRNA does not require cap-snatching. The mechanism is shown in 
Figure 9. 
 
 
Figure 9. Transcription of vRNA to cRNA and back (Zhang et al, 2010) 
 
The transcription from vRNA to cRNA is primer independent and is believed to be 
initiated through the addition of an adenine or guanine by host 
ribonucleotidyltransferase to the 3’-end of vRNA. Then the viral RdRP starts 
transcription from the uracil until the 5’ end to form the cRNA (Zhang et al, 2010) 
 
The transcription back to vRNA is started at uracil(-4). After the RdRP gets stuck at the 
uracil(-6), the AG dinucleotide is relocated to the 3’-end and permits the RdRP to read 
till the end (Zhang et al, 2010 and 2011).  
 
Translation into proteins 
Here non-structural protein 1 (NS1) plays an important role. It minimizes host 
translation by inhibiting cleavage and polyadenylation specificity protein (CPSF) and 
poly (A)-binding protein II (PABII). Without these proteins pre-mRNA cannot be spliced 
and polyadenylated, a requirement for translation. The translation of viral proteins is 
not affected, because an alternative mechanism to add a poly-A tail is used (Nemeroff 
& Qian, 1995). 
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When the (+)mRNA is ready for translation, it travels to the ribosomes where the 
proteins are produced. At the same time, unmodified (+)RNA serves as a template 
(cRNA) to produce more (-)RNA strands for the assembly of new viruses. The envelope 
proteins HA, NA and M2 are transported through the golgi-apparatus to the cell 
membrane. To prevent a conformational change of HA induced by the low pH in the 
trans-golgi network, virus protein M2 also functions to neutralize the acidic pH in the 
vesicles. The core proteins of the virus are made entirely in the cytosol. M1 proteins 
interact with the C-terminal domains of HA and NA and form parts with high HA and 
NA density on the membrane. Newly synthesized RNPs can then interact with the M1 
to form a new virus particle. 
 
PB1, PB2, PA, NP, NS1 and NEP are transported back into the cell nucleus after 
translation (Figure 10). PB2 and NP make use of the ‘classical import pathway’ while 
PB1 and PA form a complex that is recognized by β-importin Ran binding protein 5 
(RanBP5) (Hutchinson & Fodor, 2012). 
 
 
Figure 10. Import of newly made proteins into nucleus (Hutchinson & Fodor, 2012) 
14 
 
Back in the nucleus PB1, PB2 and PA form new polymerases resulting in more 
transcription. NP binds vRNA to produce vRNPs so they can leave the nucleus with the 
help of M1 and NEP.  M1 is thought to interact with the vRNP, allowing the formation 
of a vRNP-M1-NEP complex. This complex can be bound by chromosome region 
maintenance 1 protein (Crm1) and is subsequently recognized by Ran which traffics 
the vRNP through the nuclear membrane (cf. Figure 7). In the cytosol M1 remains 
bound and prevents the vRNP from re-entering the nucleus (Cros & Palese, 2003). 
 
Assembly of new particles  
The budding of new particles only happens at the apical side of polarized epithelial 
cells.  This way the virus is released back into the respiratory tract and can easily infect 
new cells. This also causes the high transmission from person to person. When a 
person is infected with influenza, it is important to cover nose and mound when 
coughing or sneezing, wash hands regularly and keep more distance from other people 
to prevent transmission (WHO). 
 
Release from host cell  
After budding, the virions are still attached to the cell membrane through the binding 
of the HA with sialic acid bound to glycoproteins. To release the virion, the virus 
possesses NA which is able to cleave this binding. NA is also a target for antiviral drugs 
that block the release of new virions. This way they prevent the virus from spreading, 
but they don’t affect its synthesis (Bouvier & Palese, 2008; Samji, 2009) 
 
Cell death 
Infection with IAV triggers apoptosis, which is an immune reaction to prevent the virus 
from replicating in infected cells. However the virus is still able to make thousands of 
new virions before cell lysis occurs. 
 
Despite the small amount of viral proteins, influenza A viruses are able to replicate very 
successfully in mammalian cells. Two surface proteins, HA and NA, are very important 
for binding to and releasing from target cells. The most important role of M2 is the 
acidification of the interior of the virion which leads to the dissociation of the M1-vRNP 
complexes. To get into the nucleus, the virus is able to trick the host cell and travel 
through the nuclear pore complexes. Once arrived in the nucleus, transcription is done 
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by PB1, PB2 and PA and requires cap-snatching. The translation is done by host 
cellular proteins. This means that the virus is very dependent on host cells for their 
replication cycle. 
 
2.3.3 Genetic Variation 
 
Genetic variation in IAV is driven by two different processes: antigenic drift and 
antigenic shift. A direct consequence of those processes is that IAV can become 
resistant to antiviral drugs and bypass human immunity. 
 
Antigenic drift  
Influenza A RdRP lacks exonuclease proofreading capability and thereby IAV are 
subject to high mutation rates. Point mutations occur at rates from 1x10-3 to 8x10-3 per 
site per year (Taubenberger & Cash, 2010). Substitutions at antigenic sites of 
structural proteins can lead to poor binding of antibodies by steric interference, 
energetically unfavorable binding or obscuration of the antibody binding by the 
introduction of new oligosaccharide attachment sites (Rappuoli et al, 2010). The same 
problem occurs with drugs that target specific structures determined by amino acid 
sequences. Mutations can change the affinity of the drugs by altering hydrophobic 
interactions, hydrogen bonds, etc. Viruses that are poorly recognized by the immune 
system are more favorable to spread throughout the population. 
 
Antigenic shift 
When a host cell is coinfected by two different types of IAV, a more drastic change can 
occur. The viruses can exchange segments which cause a new hybrid virus to be 
formed. It is called antigenic shift when the reassortment involves HA and/or NA gene 
segments. Antigenic shift is important for the evolution of IAV. Pigs can be infected by 
both avian and human IAV leading to reassortant IAVs that have potential to infect 
humans and are therefore labeled as “mixing vessels” (Ma et al., 2009). The 
introduction of new subtypes of HA and/or NA can lead to epidemics if there are no 
antibodies present in the human population (Taubenberger & Cash, 2010). 
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2.4 Immune System 
 
IAV trigger the immune system when entering the body. This results in the excretion of 
interferons and chemokines/cytokines. A few important cytokines/chemokines and their 
functions are shown in Table 2. Chemokines attract cells of the innate immune system 
to fight the infection. They also induce proliferation of lymphocytes which are part of 
the adaptive immune system. The innate immune system acts immediately after 
infection, while it takes a few days for the adaptive immune system to be fully 
activated (Madigan, 2010). 
 
 
Table 2. Examples of major immune cytokines and chemokines (Madigan, 2010) 
 
As seen in Figure 11, immune cells are divided into two important groups: myeloid cells 
and lymphoid cells. The group of myeloid cells are active in the innate immune 
response and don’t need previous contact with pathogens to be efficiently activated. 
There are 2 distinct groups of phagocytes which differentiate from myeloid cells. 
Macrophages and dendritic cells are phagocytes which have antigen-presenting 
capabilities. A second group is granulocytes (neutrophils and mast cells) which contain 
granules with toxins or enzymes that are used to kill target cells (Madigan, 2010). 
 
The second group, lymphoid cells are activated by the innate immune cells and need 
some time before they are ready to fight the infection. They mainly consist out of T 
cells and B cells which are active in the adaptive immune response. B cell receptors 
(BCR) on the surface of B cells can bind the corresponding antigen and digest it. The 
antigen is cleaved and presented to helper T cells by a histocompatibility molecule 
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(MHC). When a T helper cell binds the B cell, it starts producing lymphokines that 
stimulate mitosis of B cells. Two types of B cells will be made, B plasma cells that 
produce high quantities of soluble antibodies and B memory cells that bear copies of 
the activated BCR on their surface. Antibodies can neutralize antigens and enhance 
their recognition by phagocytes. If there was contact with a pathogen before, the 
adaptive immune response will occur faster thanks to memory B-cells (Madigan, 2010). 
A third group of lymphocytes, natural killer cells (NK cells), are lymphocytes that are 
active in the innate immune system. They constantly scan MHC for foreign protein 
fragments and kill target cells with perforins and granzymes that induce apoptosis. 
They can also recognize virus infected cells as the expression of MHC is often 
disrupted. Cells that have no or few MHC on their membranes are also killed by NK 
cells. 
 
 
Figure 11. Classification of immune cells (Madigan, 2010) 
 
IAV target the human lung epithelial cells. When cells are infected with IAV, they only 
show a weak cytokine and chemokine response. The main attributors to the antiviral 
response are the macrophages and dendritic cells. They are located very close to the 
epithelium and can produce high quantities of Tumor necrosis factor (TNF)α and type I 
interferons (IFNs). As seen in Figure 12, these IFNs consequently trigger a stronger 
second cytokine/chemokine response at a later stage of the infection (Veckman et al., 
2006). 
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Figure 12. Interaction between epithelium and macrophages/dendritic cells (Veckman et al, 
2010) 
 
After digestion of the pathogen, they also serve as antigen-presenting cells (APC) that 
initiate the adaptive immune system. Dendritic cells have the same function as 
macrophages, but are present in body tissues instead of in the blood. After infection, 
these APC migrate to lymph nodes and activate T- and B-lymphocytes by presenting 
the antigen.  
 
2.4.1 Recognition by Innate Immune System 
 
Influenza viruses are detected by several pattern recognition receptors (PRRs). The 
most investigated ones are Toll-like receptors (TLRs), retinoic acid inducible gene-I-like 
receptors (RLRs) and oligomerization domain NOD-like receptors (NLRs). The 
responses of the innate immune systems are complex and often redundant, which 
means that the same outcome can be achieved through different routes.  
 
Toll-like receptors  
Toll-like receptors are transmembrane proteins. Humans have 10 types of TLRs that 
are located at the cell surface or in case of TLR3, -7, -8 and -9 at the membrane of 
intracellular compartments. They recognize pathogen associated molecular patterns 
(PAMPs) such as lipopolysaccharides (TLR4), flagellin (TLR5) and nucleic acid motifs 
(TLR3, -7, -8 and -9) from fungi, parasites, micro-organisms and viruses. The 
horseshoe shaped ectodomain of the receptors contains leucine rich repeats (LRR) and 
is responsible for PAMP recognition. A transmembrane domain connects the 
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ectodomain with the cytoplasmic domain which is called the Toll⁄IL-1 receptor 
homology (TIR) domain. The recognition of a PAMP induces the dimerization of TLRs 
and their TIR domains. All TLRs except TLR3, which is using TIR domain-containing 
adaptor protein inducing IFN-β (TRIF) as an adaptor molecule, use a pathway that is 
very similar to the IL-1 receptor and includes the recruitment of myeloid differentiation 
primary response gene 88 (MyD88) to initiate signal transduction. TLR4 uses both 
MyD88 and TRIF pathways (Jensen & Thomsen, 2012). 
 
The types of TLR that are involved in IAV recognition are Toll-like receptor 3 (TLR3) 
and Toll-like receptor 7 (TLR7). They are located in the endosomal membrane and 
sense the presence of respectively dsRNA and ssRNA. Although IAV is an ssRNA virus, 
dsRNA is formed as intermediate during replication and thus IAV can be detected by 
TLR3. The signalling pathways are illustrated in Figure 13 (Jensen & Thomsen, 2012). 
 
 
Figure 13. TLR pathways (Jensen & Thomsen, 2012) 
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TLR3 uses TRIF as adaptor molecule and is able to recruit TNF receptor associated 
factors (TRAF) members TRAF6 and TRAF3. TRAF6 leads to the activation of 
transcription factor NF-κB via the TAK1-dependent IKKγ-NEMO pathway and a TAK1-
independent pathway initiated by Receptor-interacting protein 1 (RIP-1). TRAF6 also 
induces the mitogen-activated protein kinases (MAPK) pathway that activates the 
transcription factor AP-1. Together NF-κB and AP-1 induce the expression of 
proinflammatory genes (interleukins: (pro-) IL-1β, IL-6, (pro-)IL-18) and genes 
contributing to adaptive immune response (TNF). TRAF3 associates with TRAF family 
member-associated NF-κB activator binding kinase 1 (TBK1), and IKKε. The complex 
phosphorylates interferon regulatory transcription factor (IRF) 3 which leads to 
dimerization and transcription of IFN-α4 and IFN-β genes. Those IFNs cause the 
upregulation of IRF7 via a positive feedback system (see later). IRF7 is also 
phosphorylated by the TBK1-IKKε complex and regulates the transcription of IFN-β and 
IFN-α – not limited to IFN-α4 (Jensen & Thomsen, 2012). 
 
TLR7 on the other hand uses the MyD88 adaptor molecule. TRAF6 is bound via 
interleukin-1 receptor-associated kinases 1 and 4 (IRAKs). Then IRAK1-TRAF6 
dissociates and the TAK1-dependent IKKγ/NEMO pathway is activated, leading to the 
translocation of AP-1 and NF-κB to the nucleus where transcription starts. In 
plasmacytoid dendritic cells (pDCs) IRF7 is also phosphorylated by IRAK1. 
Phosphorylated IRF7 then translocates to the nucleus where it regulates IFN-α and 
IFN-β expression (Jensen & Thomsen, 2012). 
 
Retinoic acid inducible gene-I-like receptors 
Retinoic acid inducible gene-I-like receptors are proteins that are located in the 
cytoplasm and sense RNA. They are aspartate-glutamate-any amino acid-
aspartate/histidine (DExD/H)-box helicases which are present in most cell types except 
pDCs. The member of interest for IAV infections is Retinoic acid-inducible gene-I (RIG-
I) as it senses cytoplasmic both ssRNA and dsRNA containing a 5’-triphosphate end 
(5’ppp) (Jensen & Thomsen, 2012). Recently it has been shown that RIG-I is able to 
recognize RNA in vRNPs. Viruses, including IAV, that contain a 5’ppp dsRNA panhandle 
structure were detected even when viral RNA synthesis was blocked. This suggests 
that the 5’ppp panhandle structure is a PAMP for RIG-I and RIG-I triggers an immune 
response at the early stage of entry (Weber et al., 2013). 
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Other members are melanoma differentiation-associated antigen 5 (MDA5) and 
laboratory of genetics and physiology 2 (LGP2). Although MDA5 nearly shares the 
same domains and structure, it has a different type of ligand: MDA5 binds long dsRNA 
fragments with a length of at least 2 kb. LGP2 lacks a caspase activation and 
recruitment domain (CARD) and thus can’t bind to β-interferon promoter stimulator 1 
(IPS-1) which is needed for further signal transduction. LGP2 is thought to be a 
modulator of the innate immune system as studies showed that LGP2 binds dsRNA and 
thereby inhibits RIG-I signalling. They also suggest that LGP2 can form a complex with 
MDA5 to enhance the ability to recognize long dsRNA. RLR signalling pathways are 
found in Figure 14 (Jensen & Thomsen, 2012). 
 
 
Figure 14. RLR and inflammasome pathway (Jensen & Thomsen, 2012) 
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RIG-I and MDA5 both trigger the same pathway via the adaptor protein IPS-1 that is 
located in the mitochondrial membrane. After binding with RNA and ATP, there is a 
structural change that causes CARD to be available to IPS-1. Then IPS-1 activates RIP-
1 and IKKγ-NEMO mediated pathways, which are also activated by TRIF in the 
signalling from TLR3. As previously described, the recruitment RIP-1 ultimately leads to 
the transcription of proinflammatory cytokine genes, while IKKγ-NEMO leads to the 
production of IFN-β and upregulation of IRF7 (Jensen & Thomsen, 2012). 
 
Nucleotide-binding domain, leucine-rich repeat-containing proteins 
Nucleotide-binding domain, leucine-rich repeat-containing proteins (NLR) or previously 
named nucleotide-binding oligomerization domain receptors are intracellular proteins 
that have an important function in antiviral defence. They are responsible for 
inflammatory reaction and regulate cell death. Activation of NLRP3 results in the 
formation of the NLRP3 inflammasome as illustrated in Figure 15 (Jensen & Thomsen, 
2012). 
 
 
Figure 15. NLRP3 inflammasome and its relation to TLR and RLR pathways (Ichinoche, 2010) 
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The mechanism of activation is still unclear and it is most likely an indirect sensor of 
viral infection induced by imbalances of ionic concentrations in intracellular vesicles 
(Ichinoche, 2010). The inflammasome consists out of oligomerized NLRP3, apoptosis-
associated speck-like protein containing a CARD (ASC) and pro-caspase-1. When 
bound, pro-caspase-1 is autocatalytically cleaved and is able to turn pro-IL-1 and pro-
IL-18 in their active forms (Jensen & Thomsen, 2012). 
 
2.4.2 Further Activation by IFN-α/β 
 
Type-I Interferons or IFN-α/β are secreted after recognizing the virus. There are 13 
IFN-α and one IFN-β species that all bind to the same receptor. They induce the 
transcription of IFN stimulated genes (ISG) by activating their promoters, termed IFN 
sensitive response elements (ISRE) through the Janus activated kinase-signal 
transducer and activator of transcription (JAK-STAT) pathway which is shown in Figure 
16 (Shaw & Palese, 2005).  
 
 
Figure 16. Activation of JAK-STAT pathway (Ichinoche, 2010) 
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Type I IFN receptors consist out of two subunits interferon alpha, beta and omega 
receptor 1 (IFNAR1) and interferon alpha, beta and omega receptor 2 (IFNAR2). After 
binding to the receptor, the JAK-STAT pathway is activated. The formation of the 
STAT1-STAT2-IRF9 or STAT1-STAT1 complex, activate the ISRE and IFN-γ-activated 
site (GAS) respectively to initiate the transcription of the ISGs (Ichinoche, 2010). 
 
There are hundreds of ISGs with diverse functions, including IRF-7 which is 
upregulated for the transcription of IFN-α genes and allows a second wave with a 
much higher IFN production. Most of the ISGs inhibit cellular and viral protein 
synthesis (Shaw & Palese, 2005). 
 
Protein kinase RNA regulated (PKR) for example, is stimulated by dsRNA. It has an 
important role in a broad array of cellular processes, but it most importantly 
phosphorylates Eukaryotic Initiation Factor 2 α (eIF2α). This leads to an inhibition of 
the cellular protein synthesis and the activity of the immune system. It can also be 
activated by Protein Activator of the Interferon-induced Protein Kinase (PACT) which is 
phosphorylated as result of cellular stress (Sarkar et al., 2005). 
 
Also 2’-5’ oligoadenylate synthetases (OAS) are induced by type I IFN production. They 
are activated in presence of dsRNA and ATP and activate RNase L through dimerization 
to a ribonuclease that is able to degrade RNA (Sarkar et al., 2005). 
 
P56 is highly induced by IFN and is activated by viral stress. With the help of p48, a 
structural analogue of the Eukaryotic Initiation Factor 3e (eIF-3e), P56 can bind to 
Eukaryotic Initiation Factor 3 (eIF3) and block translation initiation by preventing the 
enhancement of the eIF2.GTP.tRNA Meti ternary complex (Sarkar et al., 2005). 
 
2.4.3 Programmed Cell Death 
 
Programmed cell death or apoptosis is an innate immune response to limit viral 
replication and a reaction to cell stress. Two major pathways that cause the cell to 
degrade are well known. Both pathways involve caspase activity. Caspases are a group 
of cysteine proteases that cleave their substrates at aspartic acid residues. Caspases 
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are present in all animal cells, but they need to be activated before they can start 
cleaving and cause apoptosis (Reed, 2000). They can be classified in two groups 
(Figure 17): initiator caspases and effector caspases. Initiator caspases require 
dimerization to be activated and have a small number of targets, including self-
cleavage of the pro-domain, the protein Bcl-2 homology 3 (BH3)-interacting domain 
death agonist (BID) and effector caspases. Effector caspases are present as inactive 
dimers and are activated by initiator caspases. Effector caspases have a large range of 
substrates and are the main attributors to apoptosis. The cell fragments are ultimately 
cleared by phagocytosis (Tait & Green, 2010). 
 
 
Figure 17. Activation of caspases (Tait & Green, 2010) 
 
Two important pathways of programmed cell death have been extensively studied and 
are shown in Figure 18. 
 
A first pathway is the extrinsic death receptor pathway. The pathway is activated when 
ligands bind to a tumor necrosis factor (TNF) family receptor. Through adaptor 
proteins like Fas-Associated protein with Death Domain (FADD), the death-inducing 
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signaling complex (DISC) that activates caspase 8 is formed (Reed, 2000; Haupt et al., 
2003) 
 
Figure 18. Apoptosis pathways (Tait & Green, 2010) 
 
A second pathway is the intrinsic pathway. It is triggered by the release of cytochrome 
c from the mitochondria by a process that is called mitochondrial outer membrane 
permeabilization (MOMP). MOMP is controlled by relative amounts of pro-apoptopic 
and anti-apoptopic proteins of the BCL-2 family. BH3-only proteins are thought to 
inhibit anti-apoptotic BCL-2 proteins that are bound to Bcl-2-associated X protein (BAX) 
and Bcl-2 homologous antagonist/killer (BAK) to inactivate them. Activation of BH3-
only proteins will thus result in the activation of BAX and BAK. A second model 
suggests that there are two types of BH3-only proteins: one that can directly activate 
BAX/BAK, but is inhibited by anti-apoptotic proteins (direct activators) and another 
group that neutralize anti-apoptotic proteins which are inhibiting the activators 
(sensitizers). Both models are illustrated in Figure 19 (Tait & Green, 2010). 
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Figure 19. BCL-2 family of proteins and BAX/BAK activation model (Tait & Green, 2010) 
 
When BAX or BAK proteins are activated by BH3-only proteins, they undergo a 
conformational change which allows them to form symmetrical dimers (Figure 20). 
Along with this, a dimer-dimer interaction interface is exposed, which allows higher-
order oligomerization. Binding of the BAK/BAX oligomers to the outer mitochondrial 
membrane causes the release of cytochrome c. It is still unclear if this happens due to 
the formation of protein channels or lipidic pores (Tait & Green, 2010). 
 
 
Figure 20. Mitochondrial outer membrane permeabilization (Tait & Green, 2010) 
 
Together with apoptotic protease-activating factor 1 (APAF-1) and procaspase-9, 
cytochrome c forms a complex called the apoptosome that causes the activation of 
caspase-9. Both caspase 8 and 9 promote the activation of the effector caspases 
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caspase-3 and caspase-7. This process is often referred to as the caspase cascade 
(Haupt et al., 2003; Tait & Green, 2010). 
 
Both pathways are connected to each other by BID. Capase-8 which is activated by the 
extrinsic pathway cleaves BID in a way that a new N-terminal glycine residue is 
formed. A myristoyl group is then added to this terminal in a process called 
myristoylation. The myristoylated BID is now able to insert into the mitochondrial 
membrane to cause MOMP by BAX and BAK (Tait & Green, 2010). 
 
2.4.4 Evasion of Immune System by IAV 
 
To be able to successfully replicate in human cells, IAV inhibits various pathways that 
are involved in the formation of immune responses. Tests with both wild type influenza 
A and mutant delNS1 show that infection with wild type IAV results in a low production 
of IFN-α and IFN-β, while delNS1 results in much higher concentrations. It is concluded 
that NS1 is able to inhibit the activation of transcription factors which results in IFN 
production (Talon et al., 2000). 
 
NS1 is shown to interact with tripartite motif-containing protein 25 (TRIM25), a protein 
that is needed to ubiquinate and activate RIG-I. By preventing TRIM25 oligomerization, 
the RIG-I pathway is blocked (Gack et al., 2009). It also prevents the inhibition of 
cellular translation by PKR by binding it (Li et al., 2006). Because NS1 binds and masks 
dsRNA, it prevents the activation of the OAS/RNase L-pathway which in normal 
circumstances would lead to the degradation of RNA (Min & Krug, 2006).  
 
Not only NS1 has immune repressing properties, M2 and NP also regulate PKR by 
activating P58IPK which is a cellular inhibitor of the PKR phosphorylation. Later in the 
infection, M2 is produced and disables P58IPK again, which leads to the inhibition of 
protein synthesis and cell apoptosis. This helps the virus to release from the cell 
membrane (Kreijtz et al., 2011). 
 
PB2 also plays an important role in regulating host anti-viral responses as it is able to 
inhibit IPS-1, the adaptor molecule used in RIG-I signaling. PB2 consequently limits the 
transcription of IFN-β (Iwai et al, 2010). 
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2.4.5 PI3K/Akt Pathway 
 
NS1 also activates the phosphatidylinositol-3-kinase (PI3K)/Akt pathway. Figure 21 
shows ten proteins that are regulated by Akt. The PI3K/Akt pathway has functions 
ranging from cell survival, proliferation, growth, angiogenesis and glucose uptake to 
the cell metabolism (Manning & Cantley, 2007).  
 
 
Figure 21. Ten proteins regulated by Akt (Manning & Cantley, 2007) 
 
It is shown that PI3K is needed in a very early step of the viral replication cycle as 
inhibition of PI3K leads to accumulation of virus particles at the cell surface. It is 
thought that IAV attachment induces an early and short peak of PI3K activation during 
viral attachment, but the mechanism it not known yet (Ehrhardt & Ludwig, 2009). 
 
At later stages PI3K is activated for a longer time by viral NS1 protein. NS1 can bind 
the p85 regulatory subunit PI3K and activate it. This leads to the suppression of 
apoptosis due to inactivation of proapoptotic proteins such as BAD, procaspase-9 and 
glycogen synthase kinase-3β (GSK-3β) by phosphorylation. By suppressing premature 
apoptosis, the virus ensures successful replication (Ehrhardt et al., 2007; Ehrhardt & 
Ludwig, 2009). 
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2.5 Antiviral Drugs 
 
Drugs against influenza traditionally target viral genes to inhibit the replication within 
the human cells. By using this approach the risk of cell toxicity is low, because of their 
specificity. On the other side viral proteins are few in number and viruses can develop 
resistance against drugs due to antigenic drift/shift (Schang et al., 2001). 
 
To overcome this problem an alternative view can be used. Viruses often use cellular 
mechanisms to replicate. Influenza A for example, needs the help of cellular RNA-
polymerase II to provide the m7G-cap of the mRNA. IAV also target some pathways to 
inhibit the cytokine/chemokine production of cells, whereby adjacent cells don’t get 
warned and replication can proceed unrestricted. By targeting these mechanisms, viral 
propagation can be reduced or even stopped. An overview of the 
advantages/disadvantages of both approaches is shown in Table 3 (Schang et al., 
2001). 
 
Table 3. Comparison between targeting viral proteins and cellular proteins (Schang et al., 2001) 
Target Advantages Disadvantages 
Viral protein  Specificity (-> safety)  Selection for drug-resistant 
mutants 
 Limited number of targets 
 Narrow specificity (that is, one 
virus or one virus family) 
 Viral pathogen must be isolated 
and its proteins must be 
characterized 
Cellular protein  Selection for drug-resistant 
mutants less likely to occur 
 Large number of potential 
targets 
 Broad specificity (that is, all 
viruses that require the 
targeted cellular proteins) 
 Viral proteins need not be 
characterized 
 Potential for toxicity 
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The main advantages of targeting cellular proteins is that viral proteins are less subject 
to mutations and the drugs can cover a big range of viruses that require the targeted 
pathway. When developing these drugs, cytotoxicity has to be monitored closely as the 
targeted protein can be essential for the organism (Schang et al., 2001). 
 
2.5.1 Virus Directed Drugs 
 
The earliest approach to develop antivirals was targeting the viral genes. These 
antivirals have saved many lives, but unfortunately many virus isolates have developed 
resistance against them. In this chapter, two groups of virus directed antivirals will be 
discussed. 
 
Adamantan(amin)e derivates  
Amantadine is the first drug found to inhibit IAV replication. When endosomes are 
travelling towards the cell nucleus, the pH starts to drop. Matrix 2 (M2) proteins are 
transmembrane proteins that transport protons to the interior of the virion. This 
acidification helps the release of vRNPs from M1. Amantadine stops this process by 
blocking the interior channel of the tetrameric M2 helix bundle (Sansom & Kerr, 1993). 
The use of the drugs has been limited because of the rapid emerge of drug resistance 
and the transmissibility of drug-resistant viruses. In the 2005-2006 U.S. influenza 
season for example, 90.5% of the H3N2 and 15.5% of the H1N1 were reported 
resistant to the drug (Deyde et al., 2007) and the substitution with asparagine at the 
serine 31 was predominantly found in those isolates. Along with S31N, mutations at 
the 26, 27, 30, and 34 positions were also responsible for drug resistance. The 
locations of these mutations and the binding sites of rimantadine and amantadine are 
shown in Figure 22. Also side effects on the central nervous system were reported 
(Pielak et al., 2009). 
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Figure 22. Proposed binding sites of rimantadine and amantadine (Pielak et al., 2009) 
 
Rimantadine also acts on the M2 channels and is thought to bind to four equivalent 
lipid-facing pockets near to the Trp41 gate. It locks the channel to a closed state 
ignoring the pH drop. It is shown that rimantadine resistance occurs when serine 31 is 
mutated (Figure 23). The mutation destabilizes the helix-helix assembly and disrupts 
the drug pocket, whereby the drug affinity is dramatically reduced (Pielak et al., 2009). 
 
 
Figure 23. Disruption of the binding pocket used by rimantadine (Pielak et al, 2009) 
 
The amino acid residues in the pockets are highly conserved. They are important for 
function and mutations such as D44A show much lower proton conductance compared 
to the wild type (Pielak et al., 2009). 
 
Neuraminidase inhibitors  
Another class of antiviral drugs against influenza is neuraminidase inhibitors (zanamivir 
and oseltamivir). They are also effective against influenza B and interfere with the 
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release of progeny influenza viruses from the infected host cells. This stops the virus 
from spreading in the respiratory tract (Moscona, 2005). The drugs are also found to 
be well tolerated and both prophylactically and therapeutically active against influenza. 
(De Clerq, 2006). 
 
NA inhibitors were designed on the basis of X-ray crystallography of N2-type NAs (N2 
and N9). Zanamivir is a drug based on sialic acid, but has a guanidino group instead of 
the 4-hydroxyl group. The drug binds to the active sites of the neuraminidase proteins 
and prevents interaction with sialic acid. The active site contains 19 conserved amino 
residues, 8 of which are catalytic (R118, D151, R152, R224, E276, R292, R371 and 
Y406) and 11 structural residues (E119, R156, W178, S179, D/N198, I222, E227, 
H274, E277, N294 and E425) (Colman et al., 1993). Because the NA has a higher 
affinity for the drug than for sialic acid, cleavage of HA is effectively inhibited (Das et 
al., 2010). Zanamivir has a low bioactivity and has to be administered by inhalation in 
order to be effective (Hurt et al., 2006). 
 
Later oseltamivir, which contains a lipophilic pentyl ether chain, was developed as a 
prodrug. It can be administered orally, which makes it favorable over zanamivir. 
Oseltamivir is converted to its active form by the liver. It takes about 3-4 hours before 
the maximum drug levels are present in the respiratory tract (Hurt et al., 2006). 
 
The virus has developed two distinct mechanisms to gain resistance against 
neuraminidase inhibitors. First, mutations in NA can lead to a reduced affinity of the 
drug to the active site, which allows the virus to cleave the sialic acid. A second 
mechanism is caused by mutations in HA. The mutations alters the affinity between HA 
and its receptor. If the affinity is low enough, NA can still cleave the bond although its 
activity is strongly reduced by the drug (Govorkova et al., 2013)   
 
2.5.2 Host Cell Targeting Drugs 
 
To overcome the problem of drug resistance, a lot of research is now focused on 
modulating cellular pathways to fight viral infections. This chapter contains two 
examples on how this can be achieved. 
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vATPase inhibitors  
Cellular vacuolar ATPases (vATPase) are multisubunit proteins with an important 
function in the acidification of the endosomes. They pump protons across the 
endosomal membrane and the pH change causes the viral and endosomal membrane 
to fuse. By targeting vATPase, the virus can be stopped before membrane fusion 
occurs. Saliphenylhalamide (SaliPhe) is an attractive drug, because its cytotoxicity is 
much lower than other known vATPase inhibitors. SaliPhe has an IC50 of 1.74 ± 
0.2 µM, while other drugs have IC50’s at (sub)nanomolar scale which make them 
unattractive for antiviral use. Antiviral activity of SaliPhe ranges from 28 nM to 206 nM, 
which is significantly lower than the IC50 value in non-infected cells (Müller et al., 
2011). 
 
Table 4. Compound testing (Müller et al., 2011) 
Compound IC50 (MDCK) IC50 (A549) 
Saliphenylhalamide 1.74 ± 0.2 µM 1 ± 0.19 µM 
Bafilimycin A1 2.9 ± 0.1 nM 1.3 ± 0.2 nM 
Concanamycin A 0.56 ± 0.09 nM 0.2 ± 0.02 nM 
Archalozid B 1.4 ± 0.1 nM 0.16 ± 0.02 nM 
 
Further testing on different IAV strains has shown that SaliPhe was the most effective 
drug, but it is about 6 times less effective against H5N1 viruses. This effect has been 
described before and may rely in the fact that H5N1 viruses are less dependent to HA 
activation through endosomal pH changes (Reed et al., 2010). 
 
SaliPhe is also shown to rescue mice from a lethal IAV, while Bafilimycin A1 did not 
show any protection at concentrations that were toxic for spleen and liver (Müller et 
al., 2011). 
 
CDK inhibitors 
Cyclin-dependent Kinases (CDKs) are required for replication of many viruses which 
replicate in dividing cells e.g. adeno- and papillomaviruses. It has been shown CDKs 
are also required for the replication of viruses that can replicate in non-dividing cells 
e.g. herpes simplex virus (HSV), human immunodeficiency virus type 1 (HIV-1) and 
influenza (Schang, 2002 & Zhang et al., 2010). They are small (30-40 kD) 
35 
 
heterodimeric protein kinases which have a function in regulating the cell cycle, 
transcription and mRNA processing. Kinases change the activity of other proteins by 
adding phosphate groups. Because the concentrations of CDKs are constant during cell 
cycle, CDKs require interaction with cyclin subunits in order to get phosphorylated and 
activated by CDK-activating-kinase (CAK). Most CDKs can bind different cyclins which 
determine the activity and substrate specificity. As seen in Figure 24, cyclins are only 
present during a particular stage in the cell cycle where they promote/inhibit the 
CDK’s. To prevent the cells from going ‘backwards’ in the cell cycle, cyclins get marked 
for degradation by proteasomes. This is done by ubiquitin-protein ligases SCF or 
anaphase-promoting complex (APF/C) which polyubiquitinylate the cyclins (Lodish, 
2012). 
 
 
Figure 24. Activity of different CDKs regulated by cylins (Lodish, 2012) 
 
Pharmacological CDK inhibitors (PCI) compete with ATP and bind to the ATP binding 
pockets of CDK’s. Flavopiridol is classified as a ‘wide spectrum’ PCI, because it inhibits 
CDKs 1, 2, 4, 9 and possibly 7. It is thought that the inhibition of cellular transcription 
by flavopiridol is a direct consequence of inhibition of CDK9 (Zhang et al., 2010). 
 
The viral polymerase can bind to hyperphosphorylated cellular RNA polymerase II 
(Figure 25). In normal cells, hyperphosphorylation of serine 2 located at the carboxy-
terminal domain (CTD) is done by cyclin T/CDK9 (P-TEFb) and stimulates the 
transcription elongation which is stalled by negative elongation factors 5,6-dichloro-1-
β-d-ribofuranosylbenzimidazole sensitivity-inducing factor (DSIF) and negative 
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elongation factor (NELF). Elongation is resumed after phosphorylation of DSIF and 
dissociation of NELF (Zhang et al., 2010). 
 
 
Figure 25. CDK9 function in normal transcription (Zhang, 2010) 
 
A study by Zhang et al. (2010) reported that depletion of cyclin T1 greatly inhibited 
viral transcription and replication and that overexpression of cyclin T1 expedited the 
formation of new viruses. They suggested that it is not likely that the kinase activity of 
CDK9 is involved in the virus transcription process, but that the ability of CDK9 to 
associate with vRNP is responsible (Figure 26). Free CDK9 can bind with vRNP in the 
absence of cyclin T1, but in order to guide the vRNP to host RNA polymerase II, CDK9 
needs its presence (Zhang et al., 2010).  
 
Figure 26. Proposed mechanism of CDK9 for viral transcription (Zhang, 2010) 
 
The mechanism that Zhang et al. (2010) proposed greatly helps RdRP to find active 
RNA polymerases and steal the cap and thus enhances replication of the virus (Zhang 
et al., 2010).  
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3 Materials and Methods 
3.1 Compounds, Cells and Viruses 
 
An overview of the compounds, cells and viruses used in the study at hand is shown in 
Table 5. 
 
Table 5. Compounds, cells and viruses 
Compounds 
MK-2206 (Selleck) ABT-263 (Selleck) Perifosine (Selleck) Obatoclax (Selleck) 
Akt inhibitor VIII 
(Sigma-Aldrich) 
GDC-0068 
(ChemieTek) 
SaliPhe (Jef De 
Brabander) 
 
Cells from ATCC 
MDCK A549 NCI-H1666 NCI-H1703 
NCI-1437 Calu-1 NCI-460 NCI-H2126 
Influenza Virus strains 
A/Helsinki/P14/2009 A/Helsinki/552/2013 A/Helsinki/629/2013 A/Helsinki/551/2013 
A/Helsinki/628/2013 A/Helsinki/P15/2009 A/Helsinki/568/2013 A/Helsinki/678/2013 
A/Helsinki/526/2013 A/Helsinki/598/2013 A/Helsinki/Vi1/2009 A/Helsinki/668/2013 
A/Helsinki/604/2013 A/Helsinki/Vi2/2009 A/Helsinki/P18/2009 A/Helsinki/Vi3/2009 
A/Helsinki/543/2013 A/WSN/33 A/PR/8/34 A/Sydney/5/1997 
A/Udorn/72 A/Chicken/Nigeria/B
A211/2006 
A/Anhui/01/2013*  
* provided by the WHO Collaborating Centre for Reference and Research on Influenza at the 
National Institute for Medical Research, London, UK 
 
All compounds were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich) to 10 
mM stock solutions and stored at -80°C until use. Madin-Darby canine kidney (MDCK) 
and A549 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM , Sigma-
Aldrich) supplemented with 10% fetal bovine serum (FBS; Gibco), 2 mM L-glutamine 
(Lonza), and 50 U/mL penicillin–streptomycin mix (PenStrep; Lonza). Human non-small 
lung cancer lines (NCI-H1666, NCI-H1703, NCI-1437, Calu-1, NCI-460, NCI-H2126 
from ATCC) were cultured in RPMI 1640 medium (Lonza) supplemented with 10% FBS, 
2 mM L-glutamine, and 50 U/mL PenStrep. All cells were grown at 37°C and 5% CO2. 
38 
 
Influenza A virus strains were propagated and titered in MDCK cells. Sequence of HA of 
A/Helsinki/552/2013 was verified by Sanger sequencing. 
 
3.2 Compound Efficacy Testing 
 
The compound efficacy testing was performed in 96-well plates in MDCK, A549 and 
NCI-H1666 cells. Typically, cells were seeded in 100 μl of appropriate cell growth 
medium and grown for 24 h to reach 95% confluence. The growth medium was 
changed to appropriate virus growth medium (VGM) containing 0.2 % bovine serum 
albumin (BSA, Sigma-Aldrich), 2 mM L-glutamine, and 1 μg/ml (MDCK) or 0.4 μg/ml 
(A549 and NCI-H1666) L-1-tosylamido-2-phenylethyl chloromethyl ketone-trypsin 
(TPCK)-trypsin (Sigma-Aldrich) in DMEM (A549 and MDCK) or RPMI 1640 (NCI-H1666). 
The compounds were added into the medium, DMSO was added to the control wells. 
The cells were infected with viruses at multiplicity of infection (moi) 0.04-5 or non-
infected (mock). Cell viability was measured using Cell Titer Glo assay (CTG; Promega) 
at 24, 48 or 72 h post infection. Luminescence was read with PHERAstar FS plate 
reader (BMG Labtech). For each virus-compound pair the quantitative activity and 
toxicity score (ATS) was calculated as described in Denisova et al. (2012). ATS varies 
between -100 and +100, where negative values indicate excessive toxicity and highest 
positive values indicate most potent compounds. 
 
3.3 Virus Titration 
 
The cells were non-treated or treated with the MK2206 at noncytotoxic concentrations 
and infected with A/Helsinki/P14/2009 at moi 0.1. Supernatants were collected at 48 h 
post infection, 10-fold diluted in DMEM-based VGM and added to MDCK cells on 6-well 
plates. After 1 h the cells were overlaid with medium containing 1.2% Avicel (FMC 
Biopolymer), 0.2% BSA, 50 units/mL PenStrep, 2 mM L-glutamine, and 1 μg/mL TPCK-
trypsin in minimal essential medium and incubated for 2 days. The cells were fixed 
with 4% formaldehyde in phosphate buffer solution (PBS) for 3 h and stained with 
0.1% crystal violet in 1% methanol, 20% pure ethanol, and 3.6% formaldehyde. Virus 
titers were determined by calculating plaque forming units (PFU) (clear spots) for 
sample dilutions and expressed as PFU/mL for the sample. 
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3.4 Quantitative Real-time PCR 
 
Total cellular RNA was isolated from NCI-H1666 cells non-infected or infected with 
A/Helsinki/p14/2009 strain using the RNeasy Plus Mini Kit (Qiagen). The RNA was 
reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions. RT-qPCR was performed with 
an ABI PRISM 7500 Sequence Detection System. The TaqMan primers and probes 
(18S: Hs99999901_s1, IFN-β: Hs01077958_s1, and IL-29: Hs00601677_g1) and the 
TaqMan® Fast Advanced Master Mix from Applied Biosystems were used. The SYBR 
Green Master Mix (Applied Biosystems) was applied for the SYBRGreen runs. A mix of 
the following GAPDH oligomers (Oligomer Oy) was used: huGAPDH_r with sequence 
5'-TGA CCT TGG CCA GGG GTG CT-3' and huGAPDH_f with sequence 5'-GGC TGG GGC 
TCA TTT GCA GGG-3'. The sequences of the NS1 oligomers (Sigma Aldrich) were: 5'-
AGA AAG CTC TTA TCT CTT G (the reverse sequence) and 5'-GAA ATG TCA MGA GAC 
T (the forward sequence). The RT-qPCR data was processed and quantified as 
described by Ohman et al. (2010) and the results are represented as relative units 
(RU). 
 
3.5 Fluorimetry 
 
The fluorescence spectra were recorded using a Carry Eclipse fluorescence 
spectrophotometer (Varian/Agilent). A Hitachi U-3900 spectrophotometer was used for 
the absorbance measurements. The absorbance and fluorescence spectra of MK2206 
were measured in PBS. The pH titrations were done using a series of buffers based on 
the Hydrion Buffer Chemvelopes (Micro Essential Laboratory, USA). 
 
3.6 Automated Image Acquisition and Image Analysis 
 
The MDCK cells were grown in 96-well plates and treated with different concentrations 
of MK2206. In another experiment MDCK cells were treated with MK2206 (10 µM), and 
its combinations with saliphenylhalamide (0.4 µM), NH4Cl (20mM) or obatoclax (0.4 
µM), or non-treated. Cells were fixed with 4% paraformaldehyde (in PBS) for 20 min at 
room temperature and imaged with modular epifluorescence microscope ScanR 
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(Olympus), which is designed for fully automated image acquisition. Long working 
distance 40x (NA 0.6) and 20x (NA 0.45) objectives were used for image acquisition. A 
standard filter set for DAPI (ex. 377/50 nm) was used for visualizing the 
autofluorescent MK2206 within the cells. Every sample was made in two replicates and 
for each well, 9 different fields of view were analysed using the ScanR Analysis 
software (Olympus). An automated background correction was applied for the DAPI 
channel. The autofluorescent vesicles (size between 1-20 pixels) visible in the DAPI 
channel were defined as the main objects, using edge detection. These objects were 
counted, and their area, circularity and mean intensity were measured. The images 
were manually controlled for quality and for potential errors. The average and standard 
deviation, for the number of objects as well as for the mean intensity of the objects, 
was calculated for each sample. 
 
3.7 Immunofluorescence 
 
NCI-H1666 cells were grown on cover glasses in 6-well plates. Cells were non- or 
MK2206-treated (10 μM) and mock- or A/Helsinki/P14/2009 -infected (moi 30) on ice 
for 1h. Cells were washed twice with ice-cold VGM, overlaid with pre-wormed media 
with or without compound, and incubated at 37°C. At 1, 2, and 4 h post infection cells 
were fixed with 4% paraformaldehyde (in PBS) for 20 min at room temperature. PBS 
with 1% BSA and 0.1% Triton X-100 was used for blocking and permeabilization of the 
fixed cells and for dilution of antibodies. Viral NP and M1 were detected with rabbit 
polyclonal antibodies (1:1000; from Ilkka Julkunen, Finland); the secondary antibody 
was Alexa Fluor 488 goat anti-rabbit IgG (H+L) (1:2000; Invitrogen). Nuclei were 
counterstained with DAPI. Images were captured with a Nikon 90i microscope and 
processed with NIS Elements AR software. 
 
3.8 Phospho-protein, Transcription and Cytokine Profiling 
 
NCI-H1666 cells were non- or MK2206-treated (10 μM) and mock- or virus-infected 
with A/Helsinki/P14/2009 at moi 3. For phospho-protein profiling media was discarded 
after 4 and 12 h of infection, cells were lysed and phosphorylation profiles of 43 
kinases and 2 related substrates were analysed using human phospho-kinase array 
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according to the manufacturer’s instructions (R&D Systems). For cytokine profiling the 
supernatants were collected after 24 h and 26 different cytokines were assayed using 
the human cytokine array panel A according to the manufacturer’s instructions (R&D 
Systems). The membranes were exposed to X-ray films and the films were scanned. 
Each image was analysed with ImageJ software (NIH, USA). For the whole genome 
gene expression analysis cells were collected after 8 h and total RNA was isolated 
using RNAeasy plus mini kit (Qiagene). Illumina TotalPrep 96 RNA Amplification Kit was 
used to amplify and label the RNA. Human HT-12_V3_expression arrays were 
processed using Limma and Beadarray packages from Bioconductor suit. The raw data 
was exported from GenomeStudio and log2 transformed prior to quantile 
normalization. We applied IlluminaHumanv3.db annotation data freely available from 
Bioconductor in order to map Illumina probes to known genes and annotate the 
probes. To rank the genes in order of evidence for differential expression we computed 
moderated t-statistics and log-odds of differential expression by Empirical Bayes 
estimator. 
 
3.9 Multi-passage Experiment 
 
NCI-H1666 cells were infected with A/Helsinki/P14/2009 at moi 0.1 in presence or 
absence of MK2206. At 48 h post infection 20 µl of media was used for the next 
passage in presence or absence of the inhibitor. During passaging we increased 
MK2206 concentration from 0.1 to 10 µM. Fifteen passages were performed and the 
virus titers were determined by plaque assay. 
 
3.10 Ethics 
 
Virus experiments were carried out under BSL-2 conditions and in compliance with 
regulations of the University of Helsinki (permit No 21/M/09) and under BSL-3 
conditions and in compliance with regulations of the Centre de Recherche Public de la 
Sante/Laboratoire National de Santé. 
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4 Results and Discussion 
 
Four Akt inhibitors were tested on their ability to rescue MDCK cells from infection with 
A/Helsinki/p14/2009 (moi 3). The cell viability testing (Figure 27) done at 48 hpi 
showed that only MK-2206 was successfully inhibiting virus-mediated cell death. The 
positive ATS value indicated that the drug rescues cells at concentrations without 
excessive cytotoxicity. 
 
 
Figure 27. Compound efficacy testing of four Akt-inhibitors shows only MK-2206 was active 
against A/Helsinki/p14/2009 infection. 
 
Cell viability of mock and MK-2206 treated (3 µM) MDCK cells showed that the 
inhibition of the virus was dependent on the moi at 48 hpi. At moi 1 and higher the 
drug wasn’t able to rescue cells anymore (Figure 28). 
 
Figure 28. Inhibition of the virus by MK-2206 was dependent on the moi. 
 
These results both suggested that MK-2206 could be used as an antiviral against 
influenza A/Helsinki/p14/2009 at non-cytotoxic concentrations. 
 
As seen in Figure 29, the plaque assay of mock and MK-2206 treated (3 µm) MDCK 
cells clearly showed that the drug was able to reduce virus production at moi 0.2. After 
treating the cells with MK-2206, the virus titer dropped from 1.1 x 107 plaque forming 
units PFU to zero. 
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Figure 29. Treatment with MK-2206 brings down the virus titer to zero. 
 
The effect of MK-2206 was also tested on other influenza A(H1N1)pdm09 isolates to 
check if the antiviral effect is not limited to A/Helsinki/p14/2009. Cell viability results 
(Figure 30A) showed that 17 out of 18 isolates were sensitive to the drug, whereas 
one, influenza A/Helsinki/552/2013, was resistant to the treatment.  
 
After comparing full-genome sequences of the A(H1N1)pdm09 viruses that were used 
in the experiment, an unique A26T mutation was found in the haemaggluttinin (HA) of 
influenza A/Helsinki/552/2013. This mutation can probably be associated with MK-2206 
resistance (Figure 30B). 
 
 
Figure 30. A. Susceptibility of different influenza A(H1N1)pdm09 isolates was high, except for 
influenza A/Helsinki/552/2013. B. A26T mutation in HA that was probably responsible for 
resistance of A/Helsinki/552/2013 to MK-2206. 
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Also seasonal (H1N1 and H3N2) and potentially pandemic (H5N1 and H7N) IAV strains 
were tested on their sensitivity regarding MK-2206, but as shown in Figure 31 they 
were resistant to the treatment. H5N1 and H7N9 were tested by our collaborators, 
because BSL-3 conditions are needed to be allowed to work with them. 
 
  
Figure 31. Seasonal and potentially pandemic influenza A viruses were resistant to MK-2206. 
 
These viruses have a different structure of HA compared to A(H1N1)pdm09 viruses. 
This also suggests that resistance to MK-2206 might be due to a different HA structure 
and activity. 
 
To find a suitable human cell line to use with our assays, different untreated human 
lung cancer cell lines were tested for their susceptibility to influenza 
A/Helsinki/p14/2009 (at moi 2). Results of cell survival at 48 hpi are shown in Figure 
32A. NCI-H1666 was found to be very permissive for the virus and had a similar 
response to MK-2206 treatment as MDCK cells (Figure 32B). A plaque assay (Figure 
32C) also showed a significant drop of the virus titer (10 µM was used). NCI-H1666 will 
be used for assays that require human cell lines. 
 
  
Figure 32. A. NCI-H1666 was most permissive to influenza A/Helsinki/p14/2009. B. NCI-H1666 
had a similar response to AIV compared to MDCK cells C. A large drop in virus titer was seen 
after treatment with MK-2206. 
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A time-of-compound addition was performed to see when the drug has the largest 
effect and at what stage of replication the virus is stopped. When the drug was added 
within 2 hpi, the cells were protected against cell death measured at 24hpi (Figure 33). 
MK-2206 is most likely inhibiting early steps of replication. 
 
 
Figure 33. Time-of-compound addition showed that the virus was blocked in an early stage. 
 
To further analyse where the virus was stopped, ABT-263 was used. ABT-263 
accelerates virus mediated cell death and is triggered by the release of viral RNA into 
the cytosol (Kakkola et al., 2013). 
 
Figure 34A shows that more cells are rescued at higher concentrations of MK-2206. 
MK-2206 is thus inhibiting the virus before it enters the cytoplasm. Figure 34B 
illustrates that the concentration of ABT-263 had no effect on the efficacy of MK-2206. 
The drop at high concentrations was caused by cytotoxic effects of ABT-263. 
 
 
Figure 34. A. MK saves infected cells from ABT accelerated virus mediated cell death.  
B. Concentration of ABT-263 has no effect on the efficacy of MK-2206. 
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To confirm that MK-2206 inhibits viral replication, RT-qPCR and immunofluorescence 
microscopy were performed. The results of RT-qPCR showed (Figure 35) that MK-2206 
treated cells clearly had a lowered transcription of viral RNA (like NS1), while there was 
no change in the amount of transcription of the house-keeping genes (like GAPDH). 
Again, this confirmed that the virus is inhibited at early steps of replication. 
 
 
Figure 35. Transcription of viral protein (NS1) is inhibited, while the transcription of 
housekeeping protein (GAPDH) is unaffected. 
 
Immunofluorescence confirmed that viruses do not enter the nucleus of the cells. M1 
and NP are viral proteins that are colored green in the combined images (Figure 36). 
As they were not visible inside the nuclei (blue color), they must have been trapped in 
the endosomes. 
 
 
Figure 36. Immunofluorescence with M1 and NP antibodies showed that viral proteins were 
trapped in the endosomes after treatment with MK-2206. Scale bars are 10 µm. 
 
Another interesting fact was that MK-2206 is autofluorescent. In the pictures, small 
fluorescent particles were visible when MK-2206 is added, independent of the used 
antibody. 
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Our collaborators further investigated the fluorescent properties of the drug by 
scanning the absorbance and fluorescence spectra. As seen in Figure 37B, fluorescence 
peeked at 456 nm and was highly dependent on pH. Maximal fluorescence was 
reached between pH 5.7-6.0. 
 
 
Figure 37. Fluorometric data of MK-2206 showed that A. absorbance peaks at 259 and 354 nm.  
B. fluorescence peaks at 456 nm. C. Fluorescence is dependent on pH and peaks at pH 5.7-6.0. 
 
Fluorescence microscopy (Figure 38) showed that MK-2206 (10 µM) accumulated in 
vesicles in the cytoplasm of non-infected cells. The fixing and imaging was done at 24 
hpi. 
  
Figure 38. MK-2206 was visible in the cells as autofluorescent vesicles (scale bars are 10 µm). 
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The amount of autofluorescent objects was measured by automated image acquisition 
and image analysis from the DAPI channel at 4 hpi . As seen in Figure 39A, the amount 
of fluorescent vesicles rose when higher concentrations of MK-2206 are used. When 
compounds were added that inhibit the acidification of the endosomes (0.4 µM SaliPhe 
or Obatoclax, 20 µM NH4Cl), the amount went down (Figure 39B). Probably the 
compound did not get trapped in the endosomes anymore, because the N-atoms of 
MK-2206 were not protonated anymore at the higher pH. 
 
 
Figure 39. A. The number of fluorescent vesicles went up with rising concentrations of MK-
2206. B. When compounds were added that inhibit the acidification of the endosomes, the drug 
was no longer held inside the endosomes.  
 
In following tests the cells were treated with 10 µM MK-2206 and infected with moi 3. 
Cytokine profiling (Figure 40) revealed that MK-2206 lowered the production of 
cytokines in infected cells, including G−CSF, GM−CSF, GRO-α, IL1A, IL1RA, IL6, IL8, 
CXCL10, MIF, and CCL5. MK2206 is thus inhibiting several signalling pathways, 
including Akt-signaling and preventing the development of immune responses. As the 
levels between non infected and infected MK-2206 treated cells approximately 
remained the same, it can be concluded that MK-2206 is stopping the virus from 
releasing its vRNA into the cytoplasm. 
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Figure 40. Membrane and heatmap of cytokine profiling at 24 hpi. 
 
Phospho-protein profiling was done on MK-2206 treated cells at different timepoints. At 
4 hpi (Figure 41), phosphorylation of EGFR (Y1086) was clearly lowered.  
 
 
 
Figure 41. Membrane and heatmap of phospo-protein profiling at 4 hpi. 
 
At 12 hpi (Figure 42), phosporylation of ERK1/1 (T202/Y204), JNK (T183/Y185 and 
T221/Y223), MSK1/2 (S376/S360), AKT (S473), HSP27 (S78/S82), c-Jun (S63), Lyn 
(Y397), RSK1/2/3 (S380/S386/S377) was prevented and de-phosphorylation of p53 
(S46/S392), AMPKα1 (T183), and β-Catenin was inhibited. 
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Figure 42. Membrane and heatmap of phospo-protein profiling at 12 hpi. 
 
Whole-genome expression was done by FUGU and data analysis showed that cellular 
genes which were upregulated by A/Helsinki/p14/2009 infection returned to their 
original values. The heatmap (Figure 43) contains genes with a fold change of >2 
(upregulated) and <-2 (downregulated). Out of those 70 genes, 23 belong to immune 
response pathways. Analysis also showed that 8 genes (LPIN1, RASD1, DHCR7, 
HMGCR, SC4MOL, HMGCS1, SQLE, ABCA1) involved in the lipid biosynthesis were 
regulated by MK-2206 in non-infected cells. This finding suggests that MK-2206 might 
also play a role in the lipid metabolism. 
 
Figure 43. Whole genome gene expression profiling heatmap at 8 hpi. 
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To investigate if A/Helsinki/p14/2009 is able to become resistant to MK-2206, a multi-
passage experiment was done on NCI-H1666 cells (Figure 44). To determine the virus 
titer, MDCK cells were used.  
 
 
Figure 44. Multi-passage experiment clearly showed that the virus did not develop resistance to 
MK-2206. 
 
The virus did not become resistant to MK-2206 as virus titers only dropped after 
passage 11 (48 h per passage). This corresponds to a concentration of 2 µM which is 
in normal circumstances just enough to inhibit the infection. This indicates that 
targeting host factor might be a successful strategy to fight virus infections. 
5 Conclusion 
 
MK-2206 was found to neutralize influenza A(H1N1)pdm09 infections with an exception 
of A/Helsinki/552/2013 at early stages of replication. The results suggest that the virus 
is stopped within the endosomes and thus does not enter the cytoplasm. MK-2206 was 
also found to be autofluorescent with a maximum fluorescence at 456 nm and is 
probably involved in the lipid metabolism. A/Helsinki/p14/2009 was unable to gain 
resistance to MK-2206.  
 
In the future, a lot of research has to be done to find drugs that are active against a 
broader scale of viruses. MK-2206 is only active against influenza A(H1N1)pdm09 and 
therefore is not the drug that many people hope for. Ideally a drug would target a 
mechanism that is shared by a lot of viruses, but therefore the replication of viruses 
has to be clearly understood. 
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